Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06825312
PHASE4

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

Sponsor: Liaoning Chengda Biotechnology CO., LTD

View on ClinicalTrials.gov

Summary

The main objective of this study is to evaluate the persistence of Japanese encephalitis antibodies in participants at the age of 6, after they have followed different Japanese encephalitis vaccination schedules. Furthermore, the study will assess the immunogenicity and antibody persistence of primary immunization across different Japanese encephalitis vaccination schedules, as well as the immunogenicity following booster immunizations within these schedules. The safety of each vaccine dose will also be evaluated.

Key Details

Gender

All

Age Range

8 Months - 8 Months

Study Type

INTERVENTIONAL

Enrollment

600

Start Date

2023-11-11

Completion Date

2031-12-31

Last Updated

2025-03-11

Healthy Volunteers

Yes

Interventions

BIOLOGICAL

Japanese Encephalitis Vaccine (Vero Cell), Inactivated

0.5ml for each dose, manufactured by Liaoning Chengda Biotechnology Co., Ltd., administered in the deltoid area of lateral arm by intramuscular injection.

BIOLOGICAL

Japanese Encephalitis Vaccine, Live

0.5ml for each dose, manufactured by Chengdu Institute of Biological Products Co., Ltd., administered subcutaneously in the lower part of the deltoid area of lateral arm.

Locations (6)

Jiashan County Center for Disease Control and Prevention

Jiaxing, Zhejiang, China

Pinghu Center For Disease Control and Prevention

Jiaxing, Zhejiang, China

Dongyang Center for Disease Control and Prevention

Jinhua, Zhejiang, China

Yongkang Center for Disease Control and Prevention

Jinhua, Zhejiang, China

Yuyao Center for Disease Control and Prevention

Ningbo, Zhejiang, China

Jiangshan Center For Disease Control and Prevention

Quzhou, Zhejiang, China